NEW YORK, Oct. 16 - Orchid Biosciences has withdrawn a proposed follow-on public offering of over 21/2 million shares of new stock, the Princeton, N.J. company announced Monday.

The manufacturer of SNP scoring technology filed the follow-on public offering with the Securities and Exchange Commission September 22. The total offering was valued at $126,143,500, according to the filing, and included a total of 4,025,000 shares of common stock: the 2 1/2 million new shares, one million existing shares, and additional " green shoe" shares.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.